- Home
- CNXN vs PHVS Comparison
CNXN vs PHVS Comparison
Compare CNXN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXN
- PHVS
- Stock Information
- Founded
- CNXN 1982
- PHVS 2015
- Country
- CNXN United States
- PHVS Switzerland
- Employees
- CNXN 2580
- PHVS N/A
- Industry
- CNXN Catalog/Specialty Distribution
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- CNXN Consumer Discretionary
- PHVS Health Care
- Exchange
- CNXN Nasdaq
- PHVS Nasdaq
- Market Cap
- CNXN 1.6B
- PHVS 1.3B
- IPO Year
- CNXN 1998
- PHVS 2021
- Fundamental
- Price
- CNXN $63.33
- PHVS $24.89
- Analyst Decision
- CNXN
- PHVS Strong Buy
- Analyst Count
- CNXN 0
- PHVS 5
- Target Price
- CNXN N/A
- PHVS $35.60
- AVG Volume (30 Days)
- CNXN 87.5K
- PHVS 123.2K
- Earning Date
- CNXN 10-29-2025
- PHVS 11-12-2025
- Dividend Yield
- CNXN 0.95%
- PHVS N/A
- EPS Growth
- CNXN N/A
- PHVS N/A
- EPS
- CNXN 3.29
- PHVS N/A
- Revenue
- CNXN $2,894,353,000.00
- PHVS N/A
- Revenue This Year
- CNXN $7.92
- PHVS N/A
- Revenue Next Year
- CNXN $5.82
- PHVS N/A
- P/E Ratio
- CNXN $19.15
- PHVS N/A
- Revenue Growth
- CNXN 4.94
- PHVS N/A
- 52 Week Low
- CNXN $56.72
- PHVS $11.51
- 52 Week High
- CNXN $77.19
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- CNXN 48.27
- PHVS 62.47
- Support Level
- CNXN $62.24
- PHVS $23.20
- Resistance Level
- CNXN $63.96
- PHVS $24.02
- Average True Range (ATR)
- CNXN 1.53
- PHVS 1.36
- MACD
- CNXN -0.15
- PHVS 0.10
- Stochastic Oscillator
- CNXN 22.13
- PHVS 96.99
About CNXN PC Connection Inc.
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.